- Home
- ACT vs GKOS Comparison
ACT vs GKOS Comparison
Compare ACT & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | GKOS |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.4B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACT | GKOS |
|---|---|---|
| Price | $38.03 | $109.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $41.00 | ★ $127.71 |
| AVG Volume (30 Days) | 243.3K | ★ 594.8K |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 1.64 | N/A |
| EPS | ★ 4.36 | N/A |
| Revenue | ★ $1,224,897,000.00 | $469,820,000.00 |
| Revenue This Year | $4.60 | $31.15 |
| Revenue Next Year | $3.50 | $24.15 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | 2.40 | ★ 30.38 |
| 52 Week Low | $30.94 | $73.16 |
| 52 Week High | $41.35 | $163.71 |
Technical Indicators
Market Signals| Indicator | ACT | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 48.46 |
| Support Level | $39.16 | $109.07 |
| Resistance Level | $41.35 | $115.00 |
| Average True Range (ATR) | 0.78 | 2.70 |
| MACD | -0.24 | -1.17 |
| Stochastic Oscillator | 5.80 | 12.13 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.